AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
This week on the "The Readout LOUD" podcast: Are ADCs having a moment? Is CAR-T safe? And who's to blame for failed trials?
Are ADCs having a moment? Is CAR-T safe? And who’s to blame for failed trials?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.
What's Your Reaction?
